Petros Pharmaceuticals, Inc. Cash And Cash Equivalents At Carrying Value

• Petros Pharmaceuticals, Inc. showed a decrease of -72.2% in Cash And Cash Equivalents At Carrying Value from 2023 to 2024.
• This data is from Petros Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
• XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2021: $14.57 million | Q2 2021: $11.03 million | Q3 2021: $8.14 million | Q1 2022: $17.67 million | Q2 2022: $13.30 million | Q4 2024: $1.72 million | Q1 2025: $8.93 million | Q2 2025: $7.32 million | Q3 2025: $6.07 million.
• Over the full 5 years of available data (2020 to 2024), Petros Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 78.4%.
• Historical annual values: Fiscal year 2024: $3.71 million | Fiscal year 2023: $13.34 million | Fiscal year 2022: $9.43 million | Fiscal year 2021: $23.85 million | Fiscal year 2020: $17.14 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026